S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma

Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.